Emory University

Other

University of Georgia Research Foundation, Inc.

University of California

The United States Government As Represented by the Department of Veterans Affairs

Georgia State University Research Foundation, Inc.

The Uab Research Foundation

University of Alabama

Beth Israel Deaconess Medical Center, Inc.

Centre National De La Recherche Scientifique

Leland Stanford Junior University

Novartis Ag

Duke University

University of Pittsburgh

Yale University

Raymond F Schinazi

Dennis C Liotta

Chung K Chu

Junxing Shi

Woo-Baeg Choi

Franck Amblard

Christina Gavegnano

Jean-Pierre Sommadossi

Steven J Coats

Gilles J Gosselin

Jean-Louis Imbach

Craig L Hill

Yongseok Choi

Longhu Zhou

J Jeffrey McAtee

Joon H Hong

Kyeong Lee

Hongwang Zhang

Richard Anthony Whitaker

Jinfa Du

Tamara Rosario McBrayer

Fred Wudl

George Lommel Kenyon

Simon H Friedman

Rintje Pieter Sijbesma

Robert A Floyd

Luigi G Marzilli

Erik Alan Gustafson

Bryan D Cox

John W Mellors

Leda Bassit

Dabney W Dixon

Joyce D Fingeroth

Jong Hyun Cho

Diane L DeCamp

Martin L Bryant

Shaoman Zhou

Fardos N Naguib

Mahmoud H El Kouni

Thomas E Keane

Peng Liu

Ozkan Sari

Benjamin D Kuiper

Bradley J Keusch

Keivan Zandi

Jennifer L Hammond

Seema Mengshetti

Sebastien Boucle

Ladislau Kovari

Maureen W Myers

Zbigniew Jan Lesnikowski

Yung-Chi Cheng

Michael J Abrams

Hao Li

Bryan R Cullen

Bertil F Eriksson

Michael J Otto

Eithan Galun

Lucjan Strekowski

Ahmed Khalil

Richard Anthony Vere Hodge

Hilla Giladi

Michael W Hager

Gerald E Bossard

Anne-Marie Aubertin

Shuli Mao

William M Shafer

Robert Todd Striker

Nicolas Paul Sluis-Cremer

Lakshmi Kotra

Geraldin&eacute; Fulcrand-El Kattan

Kostantine K Manouilov

Lakshimi Kotra

Geraldine Fulcrand-El Kattan

Chum K Chung

Steven E Patterson

Roman L Wydra

Brian R Theobald

E Matthew Kennedy

Diane L De Camp

Brian David Herman

Hal P Bogerd

Chofit Chai

Anand Kornepati

Adam Mefferd

Jean-Pierre Sommmadossi

Konstantine Manouilov

Giuseppe Gumina

Youhoon Chong

Christina Gavengnano

Tamara Rosario Mcbrayer

Compounds, compositions, and methods of treatment and prevention of HIV infection are disclosed. The compounds are pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidine JAK inhibitors. Combinations of these JAK inhibitors and additional antiretroviral compounds, such as NRTI, NNRTI, integrase inhibitors, entry inhibitors, protease inhibitors, and the like, are also disclosed. In one embodiment, the combinations include a combination of adenine, cytosine, thymidine, and guanine nucleoside antiviral agents, optionally in further combination with at least one additional antiviral agent that works via a different mechanism than a nucleoside analog. This combination has the potential to eliminate the presence of HIV in an infected patient.

Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections

Compounds, compositions and methods for modulating retinoic acid receptor-like orphan receptors (ROR) and associated diseases. Methods for treatment or prophylaxis of metabolic disorders, liver disorders or diseases, including NASH, immune disorders, central nervous system disorders, or cancer are disclosed.

Modulators of orphan nuclear receptors for NASH and other metabolic disorders

Compounds, compositions and methods for preventing, treating or curing a coronavirus, picornavirus, and/or hepeviridae virus infection in human subjects or other animal hosts. Specific viruses that can be treated include enteroviruses. In one embodiment, the compounds can be used to treat an infection with a severe acute respiratory syndrome virus, such as human coronavirus 229E, SARS, MERS, SARS-CoV-1 (OC43), and SARS-CoV-2. In another embodiment, the methods are used to treat a patient co-infected with two or more of these viruses, or a combination of one or more of these viruses and norovirus.

Peptidomimetics for the treatment of coronavirus and picorna virus infections

Nucleoside compounds, which in some embodiments include an alkynyl substituent at the 4'-position, compositions and methods for treating or preventing HIV and other viral infections, particularly where the virus is present in macrophages, microglia, and primary myeloid cells, and eliminating and/or treating infection in patients infected by these viruses, are disclosed.

Combined modalities for nucleosides and/or NADPH oxidase (NOX) inhibitors as myeloid-specific antiviral agents

Compounds, compositions, and methods of treatment and prevention of HIV, including HIV-1 and HIV-2, Dengue, and Chikungunya infection are disclosed. The compounds are TREM-1 inhibitors. Combinations of these TREM-1 inhibitors and additional antiretroviral compounds, such as NRTI, NNRTI, integrase inhibitors, entry inhibitors, protease inhibitors, JAK inhibitors, macrophage depleting agents, and the like, are also disclosed. In one embodiment, the combinations include a combination of adenine, cytosine, thymidine, and guanine nucleoside antiviral agents, optionally in further combination with at least one additional antiviral agent that works via a different mechanism than a nucleoside analog. This combination has the potential to eliminate the presence of HIV, Dengue, or Chikungunya virus in an infected patient.

Use of TREM-1 inhibitors for treatment, elimination and eradication of HIV-1 infection

The present invention is directed to compounds, compositions and methods for treating or preventing Zika virus. The compounds include pyrimidine and purine nucleosides and prodrugs thereof, including certain N-hydroxycytidine nucleoside derivatives, sulfasalazine, and various entry inhibitors.

Antiviral agents and nucleoside analogs for treatment of Zika virus

The present invention is directed to compounds, compositions and methods for preventing, treating or curing Norovirus infection in human subjects or other animal hosts.

Peptidomimetics for the treatment of Norovirus infection

Compounds, compositions, and methods of treatment and prevention of Hepacivirus, Pestivirus, Flavivirus or Alphavirus infection are disclosed. The compounds are pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidine JAK inhibitors. Combinations of these JAK inhibitors and additional antiretroviral compounds, such as NRTI, NNRTI, integrase inhibitors, entry inhibitors, protease inhibitors, and the like, are also disclosed. In one embodiment, the combinations include a combination of adenine, cytosine, thymidine, and guanine nucleoside antiviral agents, optionally in further combination with at least one additional antiviral agent that works via a different mechanism than a nucleoside analog. This combination has the potential to eliminate the presence of Hepacivirus, Pestivirus, Flavivirus or Alphavirus in an infected patient.

The present invention is directed to compounds, compositions and methods for preventing, treating or curing Hepatitis B (HBV) infection in human subjects or other animal hosts. The compounds are as also pharmaceutically acceptable, salts, prodrugs, and other derivatives thereof as pharmaceutical compositions and methods for treatment, prevention or eradication of HBV infection.

Elimination of hepatitis b virus with antiviral agents

Peptidomimetics for the treatment of coronavirus and picornavirus infections

Antiviral JAK inhibitors useful in treating or preventing coronaviridae infections

Peptidomimetics for the treatment of norovirus infection

Growing community of inventors

Decatur, GA, United States of America

Raymond F Schinazi